Joseph Fokam, Desire Takou, Ezechiel Ngoufack Jagni Semengue, Georges Teto, Grace Beloumou, Beatrice Dambaya, Maria-Mercedes Santoro, Leonella Mossiang, Serge Clotaire Billong, Fatim Cham, Samuel Martin Sosso, Edith Saounde Temgoua, Aubin Joseph Nanfack, Sylvie Moudourou, Nelly Kamgaing, Rachel Kamgaing, Joelle Nounouce Ngako Pamen, Mireille Mpoudi Ngole Etame, Anne-Cecile Z-K Bissek, Jean-Bosco N Elat, Emmanuel Eben Moussi, Vittorio Colizzi, Carlo-Federico Perno, Alexis Ndjolo
BACKGROUND: Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure might have implications on cross-resistance to dolutegravir-based antiretroviral therapies (ART). CASE PRESENTATION: We report a 65 years old Cameroonian, previously exposed to raltegravir, and failing on third-line treatment with multi-drug resistance to darunavir/r and dolutegravir...
August 26, 2020: Antimicrobial Resistance and Infection Control